Amgen vs NEC: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. NEC was founded in 1899 by Kunihiko Iwadare and is led by Takayuki Morita.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
NEC
Kunihiko Iwadare
Kunihiko Iwadare founded NEC (Nippon Electric Company) in 1899. After working for Thomas Edison in New York, he returned to Japan and formed a highly strategic joint venture with Western Electric, creating Japan's very first joint venture with foreign capital.…
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
NEC
- Koji Kobayashi1964–1988
Former CEO and Chairman
Kobayashi's C&C concept became closely associated with his name across the global electronics industry and guided NEC's investment into semiconductors and mainframe computing, helping make NEC one of the world's largest chipmakers and computer manufacturers du…
Source - Takayuki Morita2021–present
President and Chief Executive Officer
His tenure has focused on repositioning NEC away from its historical dependence on domestic telecom-equipment and PC hardware sales toward recurring software, cybersecurity, and biometric-identification revenue, an area where NEC has long-standing technology b…
Source
Timeline: Amgen and NEC side by side
1899NEC
Nippon Electric Company Founded
Kunihiko Iwadare, the Japanese sales agent for Western Electric, and W.T. Carleton, head of Western Electric's Tokyo branch, establish NEC on July 17, 1899, making it one of the first Japanese companies built on direct ties to an American electrical manufactur…
1958NEC
Computer Expansion
NEC expands from communications equipment into computers and enterprise technology.
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1982NEC
C&C Strategy
NEC promotes the integration of computers and communications as a strategic identity.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
1994NEC
Acquired Packard Bell
NEC acquired Packard Bell. NEC acquired Packard Bell in 1994.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2011NEC
PC Joint Venture with Lenovo
NEC restructures its PC business through a joint venture with Lenovo.
2018NEC
Acquired Northgate Public Services
NEC acquired Northgate Public Services for $645 million. NEC acquired UK-based Northgate Public Services from private-equity owner Cinven for about 475 million (roughly $645 million) to expand its digital-government software business into the British public se…
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2021NEC
Takayuki Morita Becomes President and CEO
Takayuki Morita, previously CFO, becomes NEC president and CEO on April 1, 2021.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2024NEC
BluStellar Strategy Launched
NEC introduces BluStellar, a value-creation model applying AI -- including a partnership integrating Anthropic's Claude -- across its IT Services and Social Infrastructure businesses.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026NEC
FY26/3 Revenue Reaches ~$24 billion (3.5827 Trillion Yen)
NEC reports higher revenue and record profit margins, with IT Services and Social Infrastructure as the key businesses.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
Questions about Amgen vs NEC
Who is the CEO of Amgen Inc. and NEC Corporation?
Amgen Inc. is led by Robert A. Bradway and NEC Corporation is led by Takayuki Morita. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs NEC Corporation?
NEC Corporation was founded in 1899 — 81 years before Amgen Inc., which was founded in 1980. NEC Corporation's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Amgen Inc..
How many employees does Amgen Inc. have compared to NEC Corporation?
Amgen Inc. employs approximately 31,500 people, while NEC Corporation employs approximately 101,800. NEC Corporation has the larger workforce at 101,800 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and NEC Corporation headquartered?
Amgen Inc. is headquartered in United States and NEC Corporation is headquartered in Japan. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Amgen Inc. and NEC Corporation?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. NEC Corporation was founded by Kunihiko Iwadare.
Which company has a longer operating history — Amgen Inc. or NEC Corporation?
NEC Corporation has been operating for approximately 127 years, making it the more established of the two companies. Amgen Inc. has been in operation for around 46 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs NEC overview